Synaptogenix (NASDAQ:TAOX) Raised to Hold at Wall Street Zen

Synaptogenix (NASDAQ:TAOX) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Synaptogenix in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Synaptogenix has an average rating of “Sell”.

Synaptogenix Stock Performance

TAOX stock opened at $3.91 on Friday. Synaptogenix has a 1 year low of $1.84 and a 1 year high of $11.98. The firm has a market cap of $29.13 million, a P/E ratio of -0.19 and a beta of 1.99. The stock has a 50-day simple moving average of $4.43 and a 200-day simple moving average of $6.05.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University.